Notice

An exclusive supply contract with Kuwait company for Anyfusion ACPi System

We signed an exclusive supply contract for Anyfusion H100 for injection with the Middle East Kuwait O Company (CAM, ACP kit set, Anyfusion V100 Pro), which is about 8.6% of Korea's population(2019), and the per capita income level, which is similar to Korea.

The number of anticancer drugs in Korea is expected to be 3.04 million (2.4 million anticancer drugs, 220,000 TPNs, 420,000 general injections), and the same conditions are expected to be 202,000 (160,000 anti-cancer drugs, 14,000 TPNs, and 28,000 general injections), but the number of anticancer drugs is expected to be more than 30 million won per year.

The number of aseptic drugs varies from country to country depending on the medical environment, health care policy, and system. In Korea, user-centered medical policies, environments, and systems are cultivated rather than patient-centered due to the correlation between medical fees and hospital profits under the national medical insurance system, so there is a significant difference in the number of preparations from most countries in the Middle East, such as Kuwait, which introduced patient-centered systems.

Due to the inefficient cost of equipment compared to the proportional daily dose of population and patients in Kuwait, the suitability of the Anyfusion ACPi system, which is a universal manual anticancer (injection) system, has been reviewed and the contract is made.

If the initial order confirms economic feasibility, efficiency, safety, and effectiveness, Company O is proceeding by expanding it to all cancer hospitals in Kuwait. I decided to visit Kuwait as soon as possible.

The Anyfusion ACPI system is a fully closed system from preparation to injection without the use of syringes, such as robots or human preparation, and is expected to have positive results due to its effectiveness, such as safety and injection accuracy.

The use of cylinder pumps for ICU and NICU is expected to expand once the anti-cancer (injection) drugs are quantified, accurate, precise injection effectiveness, and safety reviewed by FDA STeP with Anyfusion H100 are verified.

Thank you to the people in Kuwait O company and National Cancer Center for cooperating for the contract. 


Thank you!

Next Progress of the Asia-Pacific Medtech Innovation Forum(Singapore) and FDA STeP
Prev Anyfusion, FDA registration completed with STeP